Phenazopyridine hydrochloride, the active ingredient in AZO and similar urinary pain relievers, is classified as “possibly carcinogenic to humans” by the International Agency for Research on Cancer (IARC Group 2B) and listed as “reasonably anticipated to be a human carcinogen” by the U.S. National Toxicology Program. That said, these classifications are based on animal studies using long-term, high-dose exposure, not the short two-day courses typically used for UTI symptom relief.
What the Animal Studies Found
The cancer concern traces back to a 1978 study by the National Cancer Institute that fed phenazopyridine hydrochloride to rodents over extended periods. Female mice developed benign and malignant liver tumors. Rats of both sexes developed colorectal tumors, including adenomas, adenocarcinomas, and sarcomas. The fact that tumors appeared in two different species and at two different tissue sites strengthened the concern enough for regulatory agencies to take notice.
These weren’t brief exposures. The animals received the drug in their diet continuously, at doses far higher relative to body weight than what a person takes during a typical two-day course. That distinction matters, because cancer risk from chemical exposure generally depends on both dose and duration.
No Direct Evidence in Humans
No human epidemiological studies have demonstrated that phenazopyridine causes cancer in people. The IARC Group 2B classification, “possibly carcinogenic,” is a step below “probably carcinogenic” (Group 2A) and two steps below “carcinogenic to humans” (Group 1). It essentially means there’s enough animal evidence to warrant caution but not enough human data to confirm a real-world risk.
Laboratory testing does show the drug can damage genetic material. In cell-based studies conducted by the National Toxicology Program, phenazopyridine tested positive for causing mutations in mammalian cells and for triggering chromosomal abnormalities. These types of DNA damage are considered a plausible mechanism for how a substance could eventually lead to cancer, but positive results in a lab dish don’t automatically translate to cancer risk at normal human doses.
How Regulators Handle It
The FDA requires prescription versions of phenazopyridine to include a note in their labeling stating that long-term use caused tumors in the large intestines of rats and livers of mice. California added phenazopyridine hydrochloride to its Proposition 65 list of cancer-causing chemicals in 1988, which is why you may see a cancer warning on some packaging.
Despite these warnings, the drug remains available both by prescription and over the counter. Regulators haven’t pulled it from the market because the intended use is extremely short: no more than two days. The FDA specifically limits over-the-counter phenazopyridine to a maximum of two days, taken up to three times daily after meals. At the prescription level, the standard adult dose is 200 mg three times a day, also limited to two days when used alongside an antibiotic for a UTI.
Why the Two-Day Limit Matters
The two-day cap exists partly because the drug simply stops providing meaningful benefit beyond 48 hours when you’re also taking an antibiotic. But the short treatment window also keeps total exposure very low. The animal studies that produced tumors involved continuous daily dosing over the animals’ lifetimes, a scenario that has no parallel in how the drug is actually prescribed or sold.
Where risk could increase is if someone uses phenazopyridine repeatedly over months or years, perhaps self-treating chronic bladder discomfort without seeing a doctor. That pattern would move closer to the kind of sustained exposure that caused problems in animal studies. People with kidney disease face an additional concern: impaired kidneys can’t clear the drug efficiently, leading to higher concentrations in the body. Phenazopyridine is contraindicated entirely in people with kidney disease for this reason.
Putting the Risk in Perspective
Many substances carry a Group 2B classification, including pickled vegetables, aloe vera whole-leaf extract, and certain chemicals found in coffee. The designation signals that a substance deserves ongoing scrutiny, not that using it once or twice will cause cancer. For phenazopyridine specifically, the combination of animal tumor data and positive genetic toxicity results is enough to earn the label, but the absence of any confirmed human cases after decades of widespread use suggests that short-term, as-directed use carries very low practical risk.
If you’re using phenazopyridine for a day or two to manage the burning pain of a UTI while your antibiotic kicks in, that’s exactly how the drug is designed to be used. The cancer classifications are worth knowing about, particularly as a reason not to take the drug for longer than recommended or to treat it as a long-term solution for urinary discomfort.